77,053 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft purchased a new stake in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) during the fourth quarter, Holdings Channel reports. The fund purchased 77,053 shares of the medical research company’s stock, valued at approximately $4,329,000.

A number of other large investors have also recently bought and sold shares of EXAS. Geode Capital Management LLC lifted its stake in Exact Sciences by 0.3% in the third quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock valued at $211,104,000 after buying an additional 7,873 shares during the period. Champlain Investment Partners LLC boosted its stake in Exact Sciences by 10.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock valued at $169,924,000 after purchasing an additional 245,980 shares during the last quarter. Bellevue Group AG grew its holdings in Exact Sciences by 25.1% during the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock worth $98,738,000 after buying an additional 290,585 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Exact Sciences by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after purchasing an additional 45,015 shares during the last quarter. Finally, Groupama Asset Managment purchased a new position in shares of Exact Sciences in the 3rd quarter worth approximately $821,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

Exact Sciences stock opened at $54.89 on Thursday. The company’s 50-day moving average price is $57.73 and its 200-day moving average price is $59.71. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The company has a market cap of $10.16 billion, a PE ratio of -46.91 and a beta of 1.24. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to analysts’ expectations of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Exact Sciences’s quarterly revenue was up 12.8% on a year-over-year basis. On average, equities research analysts forecast that Exact Sciences Co. will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other news, CEO Kevin T. Conroy bought 19,500 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the acquisition, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. This trade represents a 1.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.36% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Craig Hallum decreased their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Benchmark restated a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. Evercore ISI dropped their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Sanford C. Bernstein raised their target price on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group dropped their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, Exact Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $72.76.

Check Out Our Latest Report on EXAS

Exact Sciences Company Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Read More

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.